Last updated on April 2019

Dose Finding Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis

Brief description of study

The overall purpose of the study is to assess the efficacy of three different doses of BI 655064 against placebo as add-on therapy to standard of care (SOC) treatment for active lupus nephritis in order to characterize the dose-response relationship within the therapeutic range, and select the target dose for phase III development.

Clinical Study Identifier: NCT02770170

Contact Investigators or Research Sites near you

Start Over

Hope Clinical Research

Kissimmee, FL United States
  Connect »

Emory University

Atlanta, GA United States
  Connect »

Northwell Health

Great Neck, NY United States
  Connect »

Hospital Hradec Kralove

Hradec Kralove, Czechia
  Connect »

HOP Rangueil

Toulouse, France
  Connect »

Queen Mary Hospital

Hong Kong, Hong Kong
  Connect »

Keio University Hospital

Tokyo, Shinjuku-ku, Japan
  Connect »

Ajou University Hospital

Suwon, Korea, Republic of
  Connect »

Addenbrooke's Hospital

Cambridge, United Kingdom
  Connect »

HOP Europ en

Marseille, France
  Connect »

Guy's Hospital

London, United Kingdom
  Connect »

HOP Civil

Strasbourg cedex, France
  Connect »

Cebu Doctors Hospital

Cebu City, Cebu, Philippines
  Connect »

Chong Hua Hospital

Cebu City, Philippines
  Connect »

Leicester General Hospital

Leicester, United Kingdom
  Connect »

Mary Mediatrix Medical Center

Lipa City, Batangas, Philippines
  Connect »

Saint Jude Heritage

Fullerton, CA United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.